2016 Hematological Malignancies

GHSG HD18 trial for advanced stages: PFS Arm A

0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0

3-year PFS 8x BEACOPP, PET+ 91.4% 8x R-BEACOPP, PET+ 93.0%

PFS

8x BEACOPP, PET+

8x R-BEACOPP, PET+

0

12

24

36

48

Time [months]

219 BEACOPP 220 R-BEACOPP Pts. at Risk

204 200

162 162

87 81

33 15